It is conceivable that US equity market structure could be tested again, and brokerage firms will be counting on the resiliency of their trading systems, which is why firms need a strong order-management system with integrated equity and options analytics, including connectivity to a breadth of other broker/dealers, exchanges, and ATSs.
The current workflow with so many “jumps” between platforms adds unnecessary complexity to an asset class which is already fragmented. We’re seeing more and more buy-side firms looking for solutions to consolidate available liquidity in one screen and to boost capacity to automate.
Vishal Pandya, chief operating officer of FlexTrade Systems, outlines how the firm’s swift response to the global pandemic has made it business (almost) as usual for their clients. Actions speak louder than words. If there is any silver lining to the Covid-19 pandemic, it would be that uncertainty and volatility reveals truth about how financial …
Intraday volatility is a substantially more important metric in this new regime. As the global health and economic situation evolves, more sudden shifts in overall volatility are likely, and historic volatility metrics will be slow to respond to such events.
Given the market’s resiliency and traders working from home during the COVID-19-fueled volatility, some market observers have questioned the centralized trading desk mentality that has been pervasive on Wall Street.
Options trading volumes and volatility skyrocketed in March as concerns over the COVID-19 virus spread across markets. In this Q&A, FlexTrade’s Vice President Equity Derivatives Rob Brogan examines the shift to electronic trading, the need for real-time tools for calculating the Greeks, and how FlexTrade supports the demand for ‘volatility trading’ in a fast-moving market.
At times like these, two major factors come into play: first, your trading technology’s ability to process and manage the data coming into the platform, and secondly, how well-established automation is within the firm.
Algo wheels are the application to trading of the idea of randomised controlled trials, which originally comes from the natural sciences. When you have some new innovation in the healthcare space, for example, you have to make sure
that a new treatment actually works and improves outcomes for patients.